Torchlight Energy Resources Inc. (NASDAQ: TRCH) shares are -57.01% down in the year-to-date (YTD) period and have moved 5.42% or $0.02 higher in the latest trading session. However, stock’s trailing 12-month performance remains nearly +15.03% lower. Comparatively, the stock is -69.97% down YTD and -7.97% over the trailing 3-month period. If we look at the shorter duration, its week performance is 6.45% and 0.58% over the month.
1 analysts offering the recommendations for the stock have a consensus rating of 3.00 to suggest that the TRCH stock is a “Hold. 0 of the 1 analysts rate the stock as a “Sell”, while 0 has rated it as “Underweight”. 0 recommend buying, with 0 rating it as an Overweight.
The stock currently trades at $0.33. The forecasts give the Torchlight Energy Resources Inc. stock a price target range of $2.70 on the higher side while at least one analyst think the stock could plunge to a low of $2.70. The two limits represent an upside potential of 87.78% or 87.78%.
Analysts estimate the earnings to decrease -800.00% in the current quarter to $0, up from the -$0.02 reported in the same quarter a year ago. Wall Street estimates earnings per share to be at an average of $0 for the next year.
Insider Transactions Summary
According to SEC data, total insider shares purchases at the company stands at 0 over the last 12 months, while SEC filings reveal that there have been 0 insider sales over the same period. Insiders have purchases 0 shares while those sold by company executives and officers stand at 0. The last 3 months have seen insiders trade a total of 0 and 0 in purchases and sales respectively.
Aptose Biosciences Inc. (NASDAQ:APTO), on the other hand, is trading around $5.47 with a market cap of $441.98M and analyst research firms have a positive stance on its shares. Analysts predict that the stock will reach $4.72 and spell out a less modest performance – a -15.89% return. Some analysts are even forecasting -$0.86 per share in earnings this year on a short term (1 year) basis.
Let us briefly look at the Aptose Biosciences Inc. (APTO) financials, with a focus on its operating details as indicated in its earnings report for the last quarter.
Company balance sheet and cash flow
APTO’s operating expenses over the recent quarter were at -$15.75 million. This represented a 199.18% of the company’s total revenues which amounted $15.88 million. With this in place, we can see that the company’s diluted EPS declined -$0.21 on the year-over-year period, shrinking to -$0.13 as given in the last earnings report.
In terms of the balance sheet & cash flow as of (Dec 2017), the total assets figure advanced to $85.32 million from $92.56 million over the previous quarter. Short term investments amounted to $28.61 million while total current assets were at $83.86 million. The cash flow from operating activities totaled -$15.25 million, significantly lower than the -$10.14 million reported in the year-ago quarter. The company’s free cash flow for the quarter was -$15.31 million.
Insiders have transacted a total of 16 times at Aptose Biosciences Inc. over the last 6 months, with insider purchases undertaken 9 times and accounting for 670,000 shares. Insider sales totaled 393,394 shares over the same period, with these deals completed in 7 transactions. Looking at these numbers, we realize that net purchases over that period are 2.0 shares. Insiders now hold a total of 6.43M shares after the latest sales, with 18.10% net shares purchased.
Insiders own 20.40% of the company shares, while shares held by institutions stand at 35.10% with a share float percentage of 64.23M. Investors are also buoyed by the number of investors in a company, with Aptose Biosciences Inc. having a total of 67 institutions that hold shares in the company.